IGFBP2 and metabolic dysfunction-associated steatotic liver disease: Recent findings indicate that in NAFLD mice, downregulation of miR-130b-5p reduces lipid accumulation by upregulating IGFBP2, whereas miR-130b-5p overexpression enhances lipid accumulation by inhibiting IGFBP2.